TCIM
CADX

TIAA CREF Investment Management’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

TIAA CREF Investment Management’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-260,957
Closed -$2.36M – 3143
2013
Q4 		$2.36M Buy
260,957
+815
+0.3% +$5.88K ﹤0.01% 2155
2013
Q3 		$1.64M Sell
260,142
-5,469
-2% -$34.8K ﹤0.01% 2337
2013
Q2 		$1.81M Buy
+265,611
New +$1.85M ﹤0.01% 2229

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TIAA CREF Investment Management's CADX Position: Q1 2014 in Review

TIAA CREF Investment Management sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 260,957 shares — an estimated $2.36M sold.

TIAA CREF Investment Management first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $2.36M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • TIAA CREF Investment Management reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • TIAA CREF Investment Management sold 260,957 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $2.36M.
  • TIAA CREF Investment Management first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • TIAA CREF Investment Management's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $2.36M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on TIAA CREF Investment Management's 13F filing for Q1 2014, filed 13 May 2014.